Figure 2. Lymphocyte changes during UPCC-11807 and UPCC-10808. (A) CD4+CD25+FOXP3+ regulatory T cell (Treg) frequency during therapy. No Treg reduction was seen following bevacizumab and metronominc cyclophosphamide. A mild (statistically significant) reduction in Treg frequency was seen after vaccine plus bevacizumab relative to pre-vaccine. Two out of three subjects exhibited marked and sustained reduction in circulating Tregs after T -cell transfer. (B) Circulating CD4:CD8 T-cell ratio as measured at baseline and at the end of the study (EOS). Longitudinal assessment of tumor-reactive T cells by interferon γ (IFNγ) ELISpot in S-01, S-02 and S-03 during UPCC-10808.